Notice



Notice date: 18/10/16

What's this about?	Effective date: 18/10/2016
ASX Trade AS	X 24 ASX TECH
✓ Trading Cle	earing Settlement ALC ASX NET
Operations Tec	chnology Market Data Rules Compliance Risk Other
<u>Title</u> Creso Pharma Limited – Admission and Commencement of Official Quotation	
<u>Description</u> Creso Pharma Limited ("Company") was admitted to the Official List of ASX Limited ("ASX") on Tuesday, 18 October 2016.	
Official quotation of the Company's securities will commence at 11:30 am AEDT (8:30 am WST) on Thursday, 20 October 2016.	
The Company raised \$5,000,000 pursuant to the offer under the prospectus dated 25 July 2016, a replacement prospectus dated 8 August 2016 and supplementary prospectus dated 16 September 2016 ("Prospectus") by the issue of 25,000,000 fully paid ordinary shares ("Shares") at an issue price of \$0.20 per Share.	
Quoted Securities:	30,027,500 fully paid ordinary shares
ASX Code:	СРН
<u>Time:</u>	11.30 am AEDT
ASX Trade Abbreviation:	CRESOPHARM
ISIN:	AU000000CPH2
Home Branch:	Perth
Industry Classification:	ТВА
Registered Office:	c/o Grange Consulting Group 945 Wellington Street West Perth WA 6005
Company Secretary:	Sarah Smith
Share Registry:	Automic Registry Services Suite 310, 50 Holt Street Surry Hills NSW 2010
Balance Date:	31 December
CHESS:	Participating. The Company will also operate an issuer sponsored subregister.

ASX Notice (continued)

<u>Dividend Policy:</u> See page 19 of the Company's replacement prospectus dated 8 August 2016.

<u>Activities:</u> Development, registration and commercialisation of pharmaceutical-grade cannabis and hemp-

based nutraceutical products and treatments.

ASX Restricted Securities: 8,000,001 fully paid ordinary shares to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.

2,500,000 options exercisable at \$0.20 each on or before 13 October 2019 to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.

250,000 options exercisable at \$0.40 each on or before 18 October 2018 to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.

20,400,000 performance rights to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.

6,412,500 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 19 January 2016.

5,700,000 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 22 February 2016.

4,342,500 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 13 April 2016.

1,395,000 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 21 June 2016.

712,500 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 14 July 2016.

135,000 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 18 July 2016.

1,000,000 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from date of issue being 13 October 2016.

400,000 options exercisable at \$0.40 each on or before 27 June 2020 to be classified as restricted securities for a period of 12 months from the date of issue being 27 June 2016.

2,886,250 options exercisable at \$0.20 each on or before 18 October 2020 to be classified as restricted securities for a period of 12 months from the date of issue being 13 October 2017.

1,000,000 performance shares to be classified as restricted securities for a period of 12 months from the date of issue being 13 October 2016.

ASX Notice (continued

What do I need to do and by when?

Instructions

For further details, please refer to the Company's replacement prospectus dated 8 August 2016.

Need more information?

Issued by

Sebastian Bednarczyk

Contact Details

08 9224 0000

Disclaimer